B Group Inc’s Palisade Bio PALI Stock Holding History

B Group Inc’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20M	Buy	11,414,285 +6,914,285	+154%	+$12.6M	14.81%	2
2025 Q4	$10.6M	Buy	+4,500,000	New	+$8.65M	7.81%	3

Other funds holding PALI

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

B Group Inc's PALI Position: Q1 2026 in Review

B Group Inc increased its Palisade Bio (PALI) stake by 154% in Q1 2026, buying an estimated $12.6M and bringing the position to 11,414,285 shares worth $20M. The position accounts for 14.81% of the portfolio, ranked #2.

B Group Inc first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

B Group Inc held 11,414,285 shares of Palisade Bio worth $20M as of Q1 2026.
B Group Inc bought 6,914,285 Palisade Bio shares in Q1 2026, an estimated $12.6M.
Palisade Bio made up 14.81% of B Group Inc's portfolio in Q1 2026, its #2 holding.
B Group Inc first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on B Group Inc's 13F filing for Q1 2026, filed 15 May 2026.